Company: MIRM
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001759425-25-000014
Chunk: 168

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 8
Chunk 168
---
1.85)$(4.00)$(4.02)Weighted-average shares of common stock outstandingBasic47,522,59440,885,12433,839,072Diluted47,522,59440,885,12433,982,493

The accompanying notes are an integral part of these consolidated financial statements.

106

Table of Contents

Mirum Pharmaceuticals, Inc.

Consolidated Statements of Comprehensive Loss

(In thousands)

 Year Ended December 31, 202420232022Net loss$(87,942)$(163,415)$(135,665)Other comprehensive income (loss):Unrealized gain (loss) on available-for-sale investments130 230 (194)Cumulative translation adjustments(2,147)1,631 12 Comprehensive loss$(89,959)$(161,554)$(135,847)

The accompanying notes are an integral part of these consolidated financial statements.

107

Table of Contents

Mirum Pharmaceuticals, Inc.

Consolidated Statements of Stockholders’ Equity

(In thousands, except share and per share data)

 Common StockAdditionalPaid-InCapitalAccumulatedDeficitAccumulatedOtherComprehensiveIncome (Loss)TotalStockholders’Equity  SharesAmountBalance as of December 31, 202130,582,596$3 $377,403 $(257,159)$(35)$120,212 Issuance of common stock in connection with asset acquisition609,305— 15,585 — — 15,585 Issuance of common stock in connection with equity incentive plans357,934— 5,438 — — 5,438 Issuance of common stock in at-the-market offerings, net of issuance costs of $7851,160,915— 21,289 — — 21,289 Issuance of common stock in connection with public offering, net of issuance costs $5,9224,000,0001 86,077 — — 86,078 Restricted common stock vested in the period122,464— — — — — Issuance of common stock in connection with Employee Stock Purchase Plan123,131— 1,834 — — 1,834 Stock-based compensation—— 27,448 — — 27,448 Net loss—— — (135,665)— (135,665)Other comprehensive loss